August 2013

A Harvard health economist and presidential campaign adviser says cost increases are on the right downward trajectory and will remain that way — as long as we keep pushing

Michael D. Dalzell

With payers no longer the lone voice for real-world outcomes, who interprets value and how it is interpreted changes

Susan Worley

Along with greater precision, they could bring opportunities to coordinate the efforts of health plans and PBMs

Minimally disruptive medicine, says the Mayo Clinic’s Victor Montori, is the kind of help today’s overwhelmed patients need


Medication Management
Thomas Reinke

Biologics and high-cost medications are becoming mainstream, creating different challenges for insurers

Evidence Review

A summary of ECRI Institute’s Emerging Technology Evidence Report

Legislation & Regulation
John Carroll

The FDA wants to significantly shorten the development time for new medications by cutting years out of the R&D process

Tomorrow’s Medicine
Thomas Morrow, MD

In two studies, Lymphoseek outperformed previous agents in identifying nodes containing metastatic malignancies

Plan Watch

The Affordable Care Act stunts the growth of these institutions, but will quality of care and competition suffer as a result?